Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia.

Samankaltaisia teoksia

• Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia.
  Tekijä: Minhas, R, et al.
  Julkaistu: (2009)
• Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
  Tekijä: Neil, A, et al.
  Julkaistu: (2003)
• Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
  Tekijä: Neil, H, et al.
  Julkaistu: (2003)
• Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.
  Tekijä: Neil, H, et al.
  Julkaistu: (2004)
• CTCA in children with severe heterozygous familial hypercholesterolaemia: Screening for subclinical atherosclerosis
  Tekijä: M. Doortje Reijman, et al.
  Julkaistu: (2024-03-01)